WO2000043392A3 - Verwendung von imidazo[1,5-a]-pyrido[3,2-e]-pyrazinonen als arzneimittel - Google Patents

Verwendung von imidazo[1,5-a]-pyrido[3,2-e]-pyrazinonen als arzneimittel Download PDF

Info

Publication number
WO2000043392A3
WO2000043392A3 PCT/EP2000/000260 EP0000260W WO0043392A3 WO 2000043392 A3 WO2000043392 A3 WO 2000043392A3 EP 0000260 W EP0000260 W EP 0000260W WO 0043392 A3 WO0043392 A3 WO 0043392A3
Authority
WO
WIPO (PCT)
Prior art keywords
pyrazinones
pyrido
imidazo
phosphodiesterase
medicaments
Prior art date
Application number
PCT/EP2000/000260
Other languages
English (en)
French (fr)
Other versions
WO2000043392A2 (de
Inventor
Norbert Hoefgen
Stefan Szelenyi
Marx Degenhard
Ute Egerland
Original Assignee
Dresden Arzneimittel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE1999102082 external-priority patent/DE19902082A1/de
Priority claimed from DE1999161302 external-priority patent/DE19961302A1/de
Priority to KR1020017009112A priority Critical patent/KR20010101603A/ko
Priority to EP00901561A priority patent/EP1144410A2/de
Priority to EEP200100377A priority patent/EE200100377A/xx
Priority to BR0007613-9A priority patent/BR0007613A/pt
Priority to SK1032-2001A priority patent/SK10322001A3/sk
Priority to EA200100792A priority patent/EA200100792A1/ru
Application filed by Dresden Arzneimittel filed Critical Dresden Arzneimittel
Priority to JP2000594808A priority patent/JP2002535330A/ja
Priority to AU22912/00A priority patent/AU2291200A/en
Priority to IL14415600A priority patent/IL144156A0/xx
Publication of WO2000043392A2 publication Critical patent/WO2000043392A2/de
Publication of WO2000043392A3 publication Critical patent/WO2000043392A3/de
Priority to IS5987A priority patent/IS5987A/is
Priority to NO20013334A priority patent/NO20013334D0/no
Priority to BG105714A priority patent/BG105714A/xx
Priority to LV010109A priority patent/LV12793B/lv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Die Erfindung betrifft die Verwendung von Imidazo[1,5-a]-pyrido[3,2-e]-pyrazinonen der Formel (1) als Inhibitoren der Phosphodiesterase 5 zur Therapie von erektiter Dysfunktion (Impotenz), die Verwendung von Imidazo[1,5-a]-pyrido[3,2-e]-pyrazinonen der Formel (1) als duale Inhibitoren der Phosphodiesterase 3 und der Phosphodiesterase 5 zur Therapie der Herzinsuffizienz, von pulmonaler Hypertonie und Gefäßerkrankungen, die mit einer Minderdurchblutung einhergehen und Verfahren zu deren Herstellung.
PCT/EP2000/000260 1999-01-20 2000-01-14 Verwendung von imidazo[1,5-a]-pyrido[3,2-e]-pyrazinonen als arzneimittel WO2000043392A2 (de)

Priority Applications (13)

Application Number Priority Date Filing Date Title
AU22912/00A AU2291200A (en) 1999-01-20 2000-01-14 Use of imidazo(1,5-a)-pyrido(3,2-e)-pyrazinones as medicaments
IL14415600A IL144156A0 (en) 1999-01-20 2000-01-14 Use of imidazo [1,5-a]-pyrido [3,2-e] -pyrazinones as medicaments
JP2000594808A JP2002535330A (ja) 1999-01-20 2000-01-14 薬剤としてのイミダゾ〔１，５−ａ〕−ピリド〔３、２−ｅ〕−ピラジノンの使用
EEP200100377A EE200100377A (et) 1999-01-20 2000-01-14 Imidaso[1,5-a]-pürido[3,2-e]-pürasinoonide kasutamine arstimitena
BR0007613-9A BR0007613A (pt) 1999-01-20 2000-01-14 Aplicação de imidazo[1,5-a]-pirido[3,2-e]-pirazinonascomo medicamento
SK1032-2001A SK10322001A3 (sk) 1999-01-20 2000-01-14 Spôsob prípravy imidazo [1,5-a]pyrido[3,2-e]pyrazínov, farmaceutické prostriedky obsahujúce takéto zlúčeniny a spôsob výroby farmaceutického prostriedku
EA200100792A EA200100792A1 (ru) 1999-01-20 2000-01-14 Применение имидазо[1,5-a]-пиридо[3,2-e]-пиразинонов в качестве лекарственных средств
KR1020017009112A KR20010101603A (ko) 1999-01-20 2000-01-14 이미다조[1,5-ａ]-피리도[3,2-ｅ]-피라지논의 약제로서의용도
EP00901561A EP1144410A2 (de) 1999-01-20 2000-01-14 Verwendung von imidazo[1,5-a]-pyrido[3,2-e]-pyrazinonen als arzneimittel
IS5987A IS5987A (is) 1999-01-20 2001-06-29 Notkun á imídazó[1,5-A]-pýridó[3,2-E]-pýrazínónumsem lyfjum
NO20013334A NO20013334D0 (no) 1999-01-20 2001-07-05 Anvendelse av imidazo [1,5-A]-pyrido[3,2-E]-pyrazinoner som legemidler
BG105714A BG105714A (en) 1999-01-20 2001-07-17 Use of imidazolo[1,5-a]-pyrido[3,2-e]pyrazinons as medicaments
LV010109A LV12793B (lv) 1999-01-20 2001-07-19 ImidazoÄ1,5-AÜ-piridoÄ3,2-EÜpirazinona ka arstniecibas lidzekla izmantosana

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE19902082.5 1999-01-20
DE1999102082 DE19902082A1 (de) 1999-01-20 1999-01-20 Verwendung von Imidazo[1,5-a]-pyrido[3,2-e]-pyrazinonen als Inhibitoren der Phosphodiesterase 5 zur Therapie von erectiler Dysfunktion und Verfahren zu deren Herstellung
DE19961302.8 1999-12-18
DE1999161302 DE19961302A1 (de) 1999-12-18 1999-12-18 Verwendung von Imidazo(1,5-a)-pyrido(3,2-e)-pyrazinonen als duale Inhibitoren der Phosphodiesterase 5 und der Phosphodiesterase 3 zur Therapie der Herzinsuffizienz, von pulmonaler Hypertonie und Gefäßerkrankungen, die mit einer Minderdurchblutung einhergehen

Publications (2)

Publication Number Publication Date
WO2000043392A2 WO2000043392A2 (de) 2000-07-27
WO2000043392A3 true WO2000043392A3 (de) 2000-09-28

Family

ID=26051406

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/000260 WO2000043392A2 (de) 1999-01-20 2000-01-14 Verwendung von imidazo[1,5-a]-pyrido[3,2-e]-pyrazinonen als arzneimittel

Country Status (23)

Country Link
EP (1) EP1144410A2 (de)
JP (1) JP2002535330A (de)
KR (1) KR20010101603A (de)
CN (1) CN1344268A (de)
AR (1) AR022318A1 (de)
AU (1) AU2291200A (de)
BG (1) BG105714A (de)
BR (1) BR0007613A (de)
CA (1) CA2296224A1 (de)
CO (1) CO5190700A1 (de)
CZ (1) CZ20012627A3 (de)
EA (1) EA200100792A1 (de)
EE (1) EE200100377A (de)
HU (1) HUP0105132A3 (de)
ID (1) ID29790A (de)
IL (1) IL144156A0 (de)
IS (1) IS5987A (de)
LT (1) LT2001078A (de)
LV (1) LV12793B (de)
NO (1) NO20013334D0 (de)
SK (1) SK10322001A3 (de)
TR (1) TR200102121T2 (de)
WO (1) WO2000043392A2 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6548490B1 (en) * 1997-10-28 2003-04-15 Vivus, Inc. Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
US6403597B1 (en) 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
JP2005513060A (ja) * 2001-12-17 2005-05-12 アルタナ　ファルマ　アクチエンゲゼルシャフト 選択的ｐｄｅ５阻害剤の新規使用
FR2835741B1 (fr) * 2002-02-12 2006-05-05 Oreal Nouveaux coupleurs 6-alcoxy-2,3-diaminopyridine utiles pour la teinture des fibres keratiniques
US6916345B2 (en) 2002-02-12 2005-07-12 L'oreal S.A. 6-alkoxy-2,3-diaminopyridine couplers for dyeing keratin fibres
DE10325813B4 (de) 2003-06-06 2007-12-20 Universitätsklinikum Freiburg Prophylaxe und/oder Therapie bei der portalen Hypertonie
CN101106997A (zh) 2004-08-17 2008-01-16 约翰·霍普金斯大学 Pde5抑制剂组合物及治疗心脏病征候的方法
ES2536906T3 (es) * 2006-12-13 2015-05-29 Aska Pharmaceutical Co., Ltd. Derivado de quinoxalina
US20090143361A1 (en) * 2007-11-30 2009-06-04 Elbion Gmbh Pyrido[3,2-E]Pyrazines, Process For Preparing The Same, And Their Use As Inhibitors Of Phosphodiesterase 10
JP2011505366A (ja) 2007-11-30 2011-02-24 ワイス・エルエルシー ホスホエステラーゼ１０の阻害剤としてのアリールおよびヘテロアリール縮合イミダゾ［１，５−ａ］ピラジン
MX370433B (es) 2011-10-10 2019-12-13 H Lundbeck As Derivados de 7h-imidazo [1-5-a] pirazin-8-ona como inhibidores de la fosfodiasterasa 9(pde9); y el uso de los mismos en el tratamiento de trastornos neurodegenerativos.
AP2014007820A0 (en) 2012-01-26 2014-07-31 Lundbeck & Co As H PDE9 inhibitors with imidazo triazinone backbone
JP5842640B2 (ja) * 2012-01-31 2016-01-13 株式会社東洋新薬 ホスホジエステラーゼ３阻害剤
WO2016022836A1 (en) * 2014-08-07 2016-02-11 Intra-Cellular Therapies, Inc. Organic compounds
US9938284B2 (en) 2014-08-07 2018-04-10 Intra-Cellular Therapies, Inc. Organic compounds
DK3303339T3 (da) 2015-07-07 2021-04-12 H Lundbeck As Pde9-inhibitorer med imidazotriazinonskelet og imidazopyrazinonskelet til behandling af perifere sygdomme

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0400583A1 (de) * 1989-05-31 1990-12-05 Berlex Laboratories, Inc. Imidazochinoxalinone, ihre Azaanaloge und Verfahren zu ihrer Herstellung
DE19510965A1 (de) * 1995-03-24 1996-09-26 Asta Medica Ag Neue Pyrido/3,2-e/pyrazinone mit antiasthmatischer Wirksamkeit und Verfahren zu deren Herstellung

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0400583A1 (de) * 1989-05-31 1990-12-05 Berlex Laboratories, Inc. Imidazochinoxalinone, ihre Azaanaloge und Verfahren zu ihrer Herstellung
DE19510965A1 (de) * 1995-03-24 1996-09-26 Asta Medica Ag Neue Pyrido/3,2-e/pyrazinone mit antiasthmatischer Wirksamkeit und Verfahren zu deren Herstellung
US5723463A (en) * 1995-03-24 1998-03-03 Asta Medica Aktiengesellschaft Pyrido 3,2-E!pyrazinones with anti-asthmatic action and processes for their manufacture

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
D.D. DAVEY ET AL.: "Novel compounds possessing potent cAMP and cGMP phosphodiesterase inhibitory activity. Synthesis and cardiovascular effects of a series of imidazo[1,2-a]quinoxalinones and imidazo[1,5-a]quinoxalinones and their aza analogues", JOURNAL OF MEDICINAL CHEMISTRY., vol. 34, no. 9, 1991, AMERICAN CHEMICAL SOCIETY. WASHINGTON., US, pages 2671 - 77, XP002141034, ISSN: 0022-2623 *

Also Published As

Publication number Publication date
SK10322001A3 (sk) 2002-07-02
HUP0105132A3 (en) 2002-12-28
ID29790A (id) 2001-10-11
JP2002535330A (ja) 2002-10-22
IS5987A (is) 2001-06-29
AU2291200A (en) 2000-08-07
TR200102121T2 (tr) 2002-01-21
NO20013334L (no) 2001-07-05
CO5190700A1 (es) 2002-08-29
BG105714A (en) 2002-02-28
CZ20012627A3 (cs) 2002-01-16
EP1144410A2 (de) 2001-10-17
IL144156A0 (en) 2002-05-23
EE200100377A (et) 2002-10-15
CA2296224A1 (en) 2000-07-20
CN1344268A (zh) 2002-04-10
LV12793B (lv) 2002-05-20
WO2000043392A2 (de) 2000-07-27
LT2001078A (en) 2002-08-26
LV12793A (lv) 2002-02-20
AR022318A1 (es) 2002-09-04
KR20010101603A (ko) 2001-11-14
EA200100792A1 (ru) 2002-10-31
BR0007613A (pt) 2001-10-30
NO20013334D0 (no) 2001-07-05
HUP0105132A2 (hu) 2002-05-29

Similar Documents

Publication Publication Date Title
WO2000043392A3 (de) Verwendung von imidazo[1,5-a]-pyrido[3,2-e]-pyrazinonen als arzneimittel
MY140872A (en) 5,7-diaminopyrazolo[4,3-d]pyrimidines with pde-5 inhibitory activity, compositions containing such derivatives and the use of such derivatives in the treatment of hypertension and other disorders
WO2001087038A3 (en) β-CARBOLINE DERIVATIVES USEFUL AS INHIBITORS OF PHOSPHODIESTERASE
PL373414A1 (en) 8-methoxy-(1,2,4)triazolo(1,5-a)pyridine derivatives and their use as adenosine receptor ligands
WO2000021926A3 (en) 6-SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDIN-4-ONES USEFUL AS CYCLIN DEPENDENT KINASE INHIBITORS
UA97468C2 (ru) Комбинация и фармацевтическая композиция, которая содержит 8-[3-аминопиперидин-1-ил]ксантины, способ ее получения и их применение в качестве лекарственного средства
TNSN06226A1 (en) Pyrazolo[1,5-a]pyrimidin-7-yl-amine derivatives for use in the treatment of protein kinase dependent diseases
WO2005030127A3 (en) Novel crystalline form of a phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor
WO2003000343A3 (en) Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
IL185611A0 (en) Novel imidazo[1,5-a]pyridine derivatives, method for preparing same and pharmaceutical compositions containing same
HUP0401104A3 (en) Beta-aminoacyl tetrahydroimidazo[1,2-a]pyrazines and tetrahydrotriazolo[4,3-a]pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes and pharmaceutical compositions containing them
WO2002066477A3 (en) Imidazopyridines
WO2002064590A3 (en) Carboline derivatives
MY117585A (en) New tetracyclic analogues of camptothecins, their preparation processes, their use as medicaments and the pharmaceutical compositions containing them.
UA81682C2 (en) Normal;heading 1;heading 2;PYRROLO[3,4-c]PYRAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS
WO2002064591A3 (en) Carboline derivatives
BR0109163A (pt) Uso de pirido[3,2-e]-pirazinonas como inibidores da fosfodieterase 5, para terapia de disfunção erétil
PL339897A1 (en) Pharmacological product, pharmacological preparation as well as application of selective pde5 inhibitors
WO2001018004A3 (de) PYRAZOLO[4,3-d]PYRIMIDINE
AU631814B2 (en) Use of bicyclic imidazole compounds for the treatment of hyperaldosteronism
MXPA03008965A (es) Uso de compuestos de imidazo [1,2-a]-piridinas sustituidas como medicamentos.
HUP9900438A2 (hu) Pirazolo[4,3-d]pirimidin-7-on-származékok alkalmazása gerincvelő-sérülés következtében fellépő impotencia kezelésére használható gyógyszerkészítmények előállítására
WO2002080911A3 (de) Verwendung substituierter imidazo[1,2-a]-pyridin-3-yl-amid- und imidazo[1,2-a]-pyridin-3-yl-aminverbindungen als arzneimittel zur behandlung von neurodegenerativen erkrankungen
WO2003072019A3 (en) Sequential therapy comprising a 20(s)-camptothecin compound and a pyrimidine base analog
WO2006067310A3 (fr) Utilisation d'un derive de dihydroim1dazopyrazine pour traiter ou prevenir la douleur

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: P-521/01

Country of ref document: YU

Ref document number: 00805307.3

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AU BG BR BY CN CZ EE GE HR HU ID IL IN IS JP KG KR KZ LT LV MK MX NO NZ PL RO RU SG SI SK TR UA UZ YU ZA

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AU BG BR BY CN CZ EE GE HR HU ID IL IN IS JP KG KR KZ LT LV MK MX NO NZ PL RO RU SG SI SK TR UA UZ YU ZA

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

WWE Wipo information: entry into national phase

Ref document number: 144156

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2001/706/KOL

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2001/05719

Country of ref document: ZA

Ref document number: 200105719

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 512944

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2000 105714

Country of ref document: BG

Kind code of ref document: A

Ref document number: 2000 594808

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2000901561

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: PV2001-2627

Country of ref document: CZ

ENP Entry into the national phase

Ref document number: 2001 20010109

Country of ref document: LV

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 200120010109

Country of ref document: LV

Ref document number: 2001078

Country of ref document: LT

Ref document number: 1020017009112

Country of ref document: KR

Ref document number: 2001/02121

Country of ref document: TR

ENP Entry into the national phase

Ref document number: 20010601

Country of ref document: UZ

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 10322001

Country of ref document: SK

Ref document number: PA/a/2001/007380

Country of ref document: MX

Ref document number: 22912/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 200100792

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: P20010611A

Country of ref document: HR

WWP Wipo information: published in national office

Ref document number: 2000901561

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020017009112

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: PV2001-2627

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 2001078

Country of ref document: LT

WWW Wipo information: withdrawn in national office

Ref document number: 2000901561

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: 2001078

Country of ref document: LT

WWR Wipo information: refused in national office

Ref document number: PV2001-2627

Country of ref document: CZ

WWW Wipo information: withdrawn in national office

Ref document number: 1020017009112

Country of ref document: KR